Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Business Wire

02-10

Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)

Richard Malamut, Chief Medical Officer at Medincell comments: "Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia."

MONTPELLIER, France, February 10, 2025--(BUSINESS WIRE)--Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

View source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2510892848"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510892848\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510892848?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 15:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2510892848","market":"us","top_or_hot":-1,"title":"Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"295\" src=\"https://s1.yimg.com/uu/api/res/1.2/xepsNRg28VytrC4pFHrw2Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/3f65ce341d187adc8d3d67617cfcba28\" title=\"\" width=\"1772\"/>\n<figcaption></figcaption>\n</figure>\n<ul>\n<li><b><a href=\"https://laohu8.com/S/MDCLF\">Medincell</a> to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)</b></li>\n</ul>\n<ul>\n<li><b>Richard Malamut, Chief Medical Officer at Medincell comments:</b> <i>\"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\"</i></li>\n</ul>\n<p><b>MONTPELLIER, France, February 10, 2025</b>--(BUSINESS WIRE)--Medincell (Paris:MEDCL):</p>\n<p>ACCESS HERE THE FULL PRESS RELEASE</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250209967526/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>David Heuzé </b><br/>Head of Corporate and Financial Communications, and ESG<br/>david.heuze@Medincell.com / +33 (0)6 83 25 21 86<br/><br/></p>\n<p><b>Grace Kim </b><br/>Head of US Financial <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> & IR<br/>grace.kim@Medincell.com / +1 (646) 991-4023<br/><br/></p>\n<p><b>Nicolas Mérigeau/ Arthur Rouillé </b><br/>Media Relations<br/>Medincell@newcap.eu / +33 (0)1 44 71 94 94<br/><br/></p>\n<p><b>Louis-Victor Delouvrier/Alban Dufumier </b><br/>Investor Relations France<br/>Medincell@newcap.eu / +33 (0)1 44 71 94 94<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompletion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals\n</h2>\n<h4 class=\"meta\">\n\n\n2025-02-10 15:00 GMT+8   <a href=\"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html\"><strong>Business Wire</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)\n\n\nRichard Malamut, Chief Medical Officer at Medincell comments: \"Our ...</p>\n<a href=\"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://finance.yahoo.com/news/completion-pivotal-phase-3-trial-070000811.html","article_id":"2510892848","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510892848","pubTimestamp":1739170800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion . Richard Malamut, Chief Medical Officer at Medincell comments: \"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\". David Heuzé Head of Corporate and Financial Communications, and ESGdavid.heuze@Medincell.com / +33 6 83 25 21 86. Grace Kim Head of US Financial Strategy & IRgrace.kim@Medincell.com / +1  991-4023. Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@newcap.eu / +33 1 44 71 94 94","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","MDCLF":"Medincell","BK4559":"巴菲特持仓","BK4585":"ETF&股票定投概念","BK4596":"哈里斯概念","BK4588":"碎股","BK4566":"资本集团","BK4007":"制药","TEVA":"梯瓦制药","BK4584":"避孕概念"},"translate_title":"Teva Pharmaceuticals完成奥氮平LAI治疗精神分裂症的关键3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1,"MDCLF":0.9},"content_text":"Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)\n\n\nRichard Malamut, Chief Medical Officer at Medincell comments: \"Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.\"\n\nMONTPELLIER, France, February 10, 2025--(BUSINESS WIRE)--Medincell (Paris:MEDCL):\nACCESS HERE THE FULL PRESS RELEASE\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250209967526/en/\nContacts\nDavid Heuzé Head of Corporate and Financial Communications, and ESGdavid.heuze@Medincell.com / +33 (0)6 83 25 21 86\nGrace Kim Head of US Financial Strategy & IRgrace.kim@Medincell.com / +1 (646) 991-4023\nNicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@newcap.eu / +33 (0)1 44 71 94 94\nLouis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@newcap.eu / +33 (0)1 44 71 94 94","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}